Quest Diagnostics Incorporated (DGX)

Quest Diagnostics stock has delivered a 76.9% total return over the past five years, and the latest valuation work using a Discounted Cash Flow (DCF) estimate points to the shares still trading at roughly a 33.3% discount to intrinsic value, even as earnings-based multiples look closer to fair.

Stocks Percent Change Top 100 Stocks Stocks Highs/Lows Stocks Volume Leaders Unusual Options Activity Options Volume Leaders · Commodities Grains Energies Alerts Pre-Market Post-Market ... All information and data in this article is solely for informational purposes. For more information please view…

DGX also launched the Flow Cytometry MRD blood test for myeloma. Henceforth, we expect the latest approval to maintain a positive market sentiment toward the stock in the upcoming days. Quest Diagnostics boasts a market capitalization of $22.48 billion at present. The Zacks Consensus Estimate for 20…

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage.

Have you been paying attention ... (DGX)? Shares have been on the move with the stock up 11.5% over the past month. The stock hit a new 52-week high of $216.87 in the previous session. Quest Diagnostics has gained 24.5% since the start of the year compared to the 1.1% move for the Zacks Medical sect…